Investing in the Cure for Chronic Disease

If Biden wins, we’re screwed!

That’s what my cousin told me last weekend, while we were having one of our obligatory drunken debates online. 

I wasn’t actually drunk though, as I’m partial to cannabis. But he throws back the tequila like a Mexican biker.

In any event, while I love my cousin, we are pretty far apart on politics.

He’s a lifelong conservative republican while I’m loyal to no party, although I tend to lean libertarian on most things.

This particular debate started when he told me that if Joe Biden wins the next election, the stock market is going to crash.  

While it’s not uncommon for Wall Street to react negatively when Dems take office, I can’t see any justification for a full-on crash being instigated by a Biden win.

In fact, JPMorgan recently opined on this, noting that a Biden win in November would be “neutral to slightly positive” for equities.

Of course, no one knows for certain.

And I’m not even sure it matters. 

After all, if you know what you’re doing, you can make money in any market.

An Overnight Double

On Monday, the NASDAQ hit a new high.

Wall Street, President Trump, and many of my colleagues cheered with multiple exclamation marks. 

But don’t mistake record highs for a healthy economy.

The fact is, this pandemic has delivered a major blow to our economy.

Unemployment numbers remain dangerously high and debt burdens have gone through the roof.  

Not to be a doom-and-gloomer, but it’s going to take years to get employment numbers back to where they need to be. And if you think we’re dealing with excessive taxation now, wait until you see what future generations are going to be on the hook for. 

But my job isn’t to shine a light on that which many of us already know.

My job is to help you make money –– no matter how unstable our economy has become.

In fact, I would argue that it’s now more important than ever to make as much money as you can, before the proverbial poop hits the fan.

And one way to do that is to invest in the companies and industries that will thrive in both good times and bad.

One company I’m very bullish on right now is a small biotech firm that’s currently conducting clinical trials on a new drug that looks like it could not only completely cure chronic diseases, but even reverse them.

I know, it sounds almost too good to be true.

And full disclosure: Clinical trials are not yet completed.

But the company just announced that it expects to release its top-line 12-week results from its Phase 2 study in Q3. This is just weeks away.

If the results are positive, this stock could literally double inside of 24 hours.  

Certainly, that’s what Peter Thiel and Jeff Bezos are banking on, as both have already invested millions in this company. And I can’t say I blame them. After all, if all goes as planned, and clinical trials are successful, this treatment for chronic diseases could be worth hundreds of billions of dollars.

This, according to the Longevity Fund, a venture capital firm that invests specifically in anti-aging related companies.

Based on their own due diligence, the good folks over at the Longevity Fund have gone on record saying that a single age-related indication could be worth a couple hundred billion dollars

That’s billion, with a “B.”

It makes sense. We’re talking about not only curing things like heart disease, diabetes, and arthritis, but even reversing these diseases.

But don’t just take my word for it.

Take a look at the data for yourself.

Take a look at the long list of billionaires that are already investing in this space.

Hell, just look at how this company’s technology works. 

Once you see what’s going on here, I’m willing to bet it won’t take you long to buy a few shares for yourself –– before those trial results come out next month.

To a new way of life and a new generation of wealth…

Jeff Siegel

Check us out on YouTube!

@JeffSiegel on Twitter

Jeff is an editor of Energy and Capital as well as a contributing analyst for New World Assets.

Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.